Ferring Pharmaceuticals SA

Four abstracts, including two oral and two poster presentations, highlight Ferring’s dedication and multi-focus approach to advancing fertility care PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals will present new data from four abstracts at the upcoming 2024 American Society for Reproductive Medicine (ASRM) Congress, being held October 19-23 in Denver, Colorado, and virtually. “We are pleased to share new data at this year’s ASRM Congress that provides healthcare professionals and fertility clinic staff with important research, findings and insights that they can apply in their clinical practice,” said Sasmira Lalwani, Senior Medical Director, Reproductive Medicine, Ferring Pharmaceuticals. “Our data presentations underscore our goal of advancing the science, supporting diverse family-building needs and providing educational resources for healthcare professionals because we understand there’s not a ‘one-size-fits-all’ approach to fertility care.” The four abstracts being presented by Ferring cover a wide range of timely and critical topics in reproductive medicine. Abstract Title Presentation Details - All times MDT Advancing Fertility Equity: Uplifting Black Women’s Voices to Design Culturally Responsive Support Solutions Poster #24 EMBARGOED UNTIL: October 21 10:45 – 11:00 a.m. Patterns of Utilization of Advanced Practice Providers in Reproductive Endocrinology: A 2023 National Survey Oral Presentation #184 EMBARGOED UNTIL: October 22 11:45 – 11:56 a.m. Impact of Gonadotropin Selection on Risk of Ovarian Hyperstimulation Syndrome (OHSS) in Predicted High Responders Undergoing Ovarian Stimulation: A Megaset-HR Trial Analysis Oral Presentation #154 EMBARGOED UNTIL: October 22 10:56 – 11:07 a.m. Assessing the Impact of an eLearning Platform for Educating Fertility Professionals Poster #652 EMBARGOED UNTIL: October 23 11:30 – 11:45 a.m. “For more than 50 years, Ferring has been relentless in our pursuit to help more people become parents by working to address the evolving needs within reproductive medicine,” said David Powley, Vice President, Reproductive Medicine and Operations, Ferring Pharmaceuticals. “ASRM is an important opportunity to share more about our contributions and long-standing investment in areas such as our product portfolio and pipeline, focus on expanding access to in vitro fertilization and work with healthcare professionals to help improve the patient experience and outcomes.” Along with the four data presentations, Ferring will also host an informative discussion entitled “Addressing Gaps and Reaching More Patients: Impacting Family Building Through Advocacy and Legislation” (October 21st at 10:05 a.m. MDT). The moderated panel discussion highlights the state and federal legislative, policy and health equity advances to expand access to family building care and infertility treatment. Moderator : Tim Clark, Director of Government Affairs, Ferring Panelists : Serena H. Chen, MD, Reproductive Endocrinologist, Division Director Emeritus & Director of Advocacy, CCRM NJ - IRMS Reproductive Medicine Michael A. Thomas, MD, Professor and Chair, Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine and Immediate Past President, American Society for Reproductive Medicine Sean B. Tipton, MA, Chief Advocacy & Policy Officer, American Society for Reproductive Medicine About Ferring Pharmaceuticals Ferring Pharmaceuticals is a privately-owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. In the United States, Ferring is a leader in reproductive medicine, and in areas of gastroenterology and orthopaedics. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Our company was founded in 1950 and is headquartered in Saint-Prex, Switzerland. Ferring employs more than 7,000 people worldwide and markets its medicines in over 100 countries. Ferring USA is based in Parsippany, New Jersey, and employs more than 900 employees. For more information, please visit , call 1-888-FERRING (1-888-337-7464), or connect with us on LinkedIn , and X (Twitter) . Contacts For more information, please contact: Lisa Perdomo Director, Brand Communications Ferring Pharmaceuticals +1-862-341-9820 lisa.perdomo@ferring.com

Computational disease model developer CytoReason has secured $80 million from Nvidia, Pfizer, Thermo Fisher Scientific and OurCrowd to equip drugmakers with predictive insights it says can improve the probability of Phase II success.  The Israeli firm plans to use the proceeds to scale its AI models into additional applications, enhance its proprietary data and establish a US hub in Cambridge, Massachusetts later this year.By providing molecular level insights, the company's technology assists therapeutic area leaders and researchers in speeding up and improving the accuracy of R&D decisions. The technology allows scientists to prioritise potential targets and indications, and stratify patient populations, while programme leaders can compare drugs across multiple diseases or multiple drugs within a single disease. Augmenting R&DPfizer first teamed up with the company in 2019 and later expanded the partnership in 2022 with a $20 million investment and licensing deal potentially worth up to $110 million by 2027.Mikael Dolsten, Pfizer’s outgoing chief scientific officer, said the company leverages CytoReason's "cutting-edge" immunology multiomics platform to augment its own R&D capabilities, generating "invaluable insights into new drug development pathways for patients."CytoReason expects the investment will enable more pharma and biotech companies to access its decision-making technology.The company has worked with several other pharmaceutical firms, including Merck KGaA, Sanofi, Ferring Pharmaceuticals and Poolbeg Pharma to make data-driven decisions in areas covering immunology, inflammation, immuno-oncology and metabolism. It has also recently expanded its disease model coverage to include central nervous system-related diseases.

Dive Brief:Agios Pharmaceuticals has agreed to sell to Royalty Pharma rights to royalties on a brain cancer drug it invented and sold to Servier.Per deal terms announced Tuesday, Agios will receive $905 million in cash from Royalty Pharma should the drug, currently known as vorasidenib, win approval from U.S. regulators. In exchange, Royalty Pharma will receive a 15% royalty on up to $1 billion in annual U.S. sales, and a 12% royalty on U.S. sales over $1 billion. Agios will keep 3% of the royalties on U.S. sales surpassing $1 billion.Royalty Pharma expects the drug to generate more than $1 billion in annual U.S. sales as well as more than $150 million in yearly royalties. The company forecasts the royalty stream to last through 2038. The FDA will decide by Aug. 20 whether to approve vorasidenib for a form of glioma.Dive Insight:The deal gives Agios an opportunity to again reap the benefits of the oncology research for which it was once known.Founded in 2007 and for years run by GV general partner David Schenkein, Agios successfully developed and won approvals of two leukemia drugs in about a decade. But Agios struggled to sell them and continued to lose money, ultimately leading the company to shift its focus to rare diseases and in 2020 sell its cancer drug portfolio to French drugmaker Servier for $1.8 billion.The deal gave Servier one of Agios marketed drugs, Tibsovo, as well as a trio of experimental medicines. One of those prospects was vorasidenib, which at the time was in advanced testing for certain types of low-grade gliomas. While Servier acquired full drug rights in the deal, Agios was promised a $200 million milestone payment upon the drugs approval in the U.S. It also kept a piece of U.S. royalties.That deal, along with the Royalty Pharma agreement announced Tuesday, gives Agios the ability to become cash flow positive without additional raises, wrote Piper Sandler analyst Christopher Raymond. Notably, Agios should now be able to fund the launches of its drug mitapivat in beta thalassemia and sickle cell disease in 2025 and 2026, respectively, he wrote in an investor note Tuesday.We see this as a smart deal for the company and also creates a sizable war chest which [Agios] can use to enhance or expand their pipeline, Raymond wrote.The deal adds to a string of recent investments by Royalty Pharma, meanwhile. Earlier this month, the company paid $525 million to buy into an autoimmune disease drug currently owned by Sanofi. Before that, the company acquired rights to Roches spinal muscular atrophy medicine Evrysdi, a cancer therapy from Ferring Pharmaceuticals and a schizophrenia drug from Karuna Therapeutics. '